Table 19 Top 10 pairs of drugs with their correlation with subtype 7 of breast cancer, considering both combined and individually
From: Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Drug1 | Drug2 | C. Cor. | Cor. 1 | Cor. 2 | C. Rank | Rank 1 | Rank 2 |
|---|---|---|---|---|---|---|---|
L-690330 | Favipiravir | − 0.93 | − 0.69 | − 0.54 | 1 | 12 | 87 |
MG-132 | Finasteride | − 0.92 | − 0.66 | − 0.55 | 2 | 18 | 83 |
TG-100801 | Phensuximide | − 0.91 | − 0.69 | − 0.61 | 3 | 11 | 37 |
Raclopride | Ketorolac | − 0.89 | − 0.65 | − 0.57 | 4 | 19 | 57 |
Hymecromone | Raclopride | − 0.88 | − 0.66 | − 0.65 | 5 | 16 | 19 |
Ruxolitinib | ADMA | − 0.87 | − 0.83 | − 0.57 | 6 | 2 | 56 |
Ruxolitinib | Dalfampridine | − 0.87 | − 0.83 | − 0.63 | 7 | 2 | 24 |
TG-100801 | AMG-232 | − 0.87 | − 0.69 | − 0.59 | 8 | 11 | 51 |
Tolvaptan | Zileuton | − 0.87 | − − 0.64 | − 0.59 | 9 | 22 | 49 |
Isbufylline | Favipiravir | − 0.86 | − 0.71 | − 0.54 | 10 | 7 | 87 |